This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Criteria used to ensure the validity of primary studies
Not stated although the study containing the meta analysis stipulated its own inclusion criteria.
Methods used to judge relevance and validity, and for extracting data
The original data were extracted from the primary studies and the life expectancy outcome was estimated by the mean survival obtained from applying Kaplan-Meier methods to that data.
Number of primary studies included
Seven studies were included.
Methods of combining primary studies
Meta-analysis.
Investigation of differences between primary studies
Five studies used the intravenous chemotherapy option whereas the other two studies used the option of symptom palliation or ad libitum intravenous chemotherapy with, in most cases, fluorouracil alone.
Results of the review
The HAI group had a mean survival time of 16.3 (SE 0.7) months versus 13.1 (SE 0.7) months for the control (no HAI) group (logrank P= 0.0009).
Measure of benefits used in the economic analysis
Gain in life expectancy was used as the benefit measure. A 5% discount rate was applied to the life years gained.
Direct costs
Quantities were not reported separately from costs. The cost items were reported separately and the costs were discounted. The cost analysis was based on costs associated with the initial procedure, chemotherapy cycles, and main complications for the duration of the patient follow-up. Overhead and capital costs were included, whereas protocoldriven costs were excluded. The cost analysis was performed from the perspective of a health care system. The source of resource utilisation data was data from the two study sites in Paris and Palo Alto. The source of unit cost data was actual data from two centres (Paris and Palo Alto), each analysed separately. The price date was 1995. The costs of symptom palliation were omitted since they were believed to be common to the study groups.
Indirect Costs
Not considered.
Currency

US dollars ($).
Sensitivity analysis
A sensitivity analysis was conducted by excluding the data for those patients receiving the symptomatic palliation option only. This was equivalent to omission of two of the studies with such a comparator, so that only five studies were
